Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advanced Life Sciences and Wyeth develop cethromycin in Asia-Pacific

This article was originally published in Scrip

Executive Summary

Advanced Life Sciences (ALS) could receive more than $100 million through an agreement with Wyeth to develop and commercialise cethromycin in the Asia-Pacific region, excluding Japan. Cethromycin (ABT-773) is a novel ketolide once-a-day oral antibiotic for the treatment of community respiratory tract infections. Mark Larsen, Wyeth's president for Asia-Pacific and nutritionals, said that, if approved, cethromycin would add to Wyeth's portfolio of existing anti-infectives, such as Tygacil (tigecycline) and Zosyn (piperacillin and tazobactam). Asia-Pacific is also a key growth region for the company, he added. Dr Michael Flavin, chairman and CEO of ALS, said that there was a need for new antibiotics in this region as market growth was outpacing the rest of the world owing to high bacterial resistance rates. Wyeth has made an up-front equity investment in ALS by buying 4.9% of ASL stock. ALS will receive milestone and regulatory payments based on successful achievement of clinical, regulatory and commercial objectives in specific markets, as well as royalty payments. The two firms will collaborate to develop additional clinical data in the region to support regulatory filings there. Elsewhere, ALS has submitted a US NDA for cethromycin for mildtomoderate community-acquired pneumonia.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts